Table 2. . Treatment-related adverse outcomes.
| Variables | Cohort A (metformin) N = 21 (42%) | Cohort B (no metformin) N = 29 (58%) | |
|---|---|---|---|
| Mean number of new metastatic site appeared while on therapy | 1.7 ± 1.6 | 2.3 ± 2 | p = 0.2 |
| New skeletal metastasis on therapy | 7 (33.3%) | 7 (24.1%) | p = 0.4 |
| New brain metastasis on therapy | 1 (4.8%) | 5 (17.2%) | p = 0.1 |
| Fatigue | 16 (76.2%) | 28 (96.6%) | p = 0.02 |
| Rash | 1 (4.8%) (G 1) | 1(3.4%) (G 1) | p = 0.8 |
| Pneumonitis | 1 (4.8%) (G 3) | 5 (17.2%) (G 3–4) | p = 0.1 |
| Acute kidney injury | 0 (0%) | 1 (3.4%) (G 3) | p = 0.2 |
| Transaminitis | 0 (0%) | 2 (6.8%) (G 3–4) | p = 0.2 |
| Colitis | 3 (14.3%) (G 2–4) |
3 (10.3%) (G 2–4) | p = 0.6 |
| Hospitalization due to treatment | 3 (14.3%) | 7 (24.1%) | p = 0.3 |
| IrAE (excluding fatigue) | 7 (38.1%) | 13 (44.8%) | p = 0.6 |
| Prednisone required for IrAEs | 6 (28.5%) | 12 (41.3%) | p = 0.3 |
IrAE: Immune-related adverse event, G (Grade of IrAE)